Physician profile
Michael Houser
NPI 1285710665
$2,467.27
in general payments reported to CMS, 2019-2025
29 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $62.72 · 2021: $97.39 · 2022: $477 · 2023: $577 · 2024: $437 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $396.61 | 2019-2025 | |
| Novo Nordisk INC | $324.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $290.69 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $257.42 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $189.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $113.25 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $112.70 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $90.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $83.50 | 2022-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $83.38 | 2021-2022 | |
| Amgen INC. | $65.42 | 2019-2025 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $49.98 | 2019 | |
| Astellas Pharma US INC | $46.68 | 2019-2024 | Veozah |
| Almatica Pharma LLC | $45.13 | 2022-2023 | Gralise, Loreev Xr |
| Merck Sharp & Dohme LLC | $40.01 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $33.16 | 2024-2025 | Immunocap |
| Sunovion Pharmaceuticals INC. | $26.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $26.11 | 2019-2022 | |
| Hologic Sales and Service, LLC | $23.38 | 2025 | Aptima, Third Wave, Thinprep 2000 Processor |
| E.R. Squibb & Sons, L.L.C. | $21.85 | 2025 | Eliquis |
| Sumitomo Pharma America, INC. | $18.89 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2023 | Jardiance |
| Azurity Pharmaceuticals, INC. | $15.88 | 2025 | |
| Amarin Pharma, INC. | $14.68 | 2019 | |
| Sanofi Pasteur INC. | $14.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.31 | 2020 | |
| Promius Pharma LLC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Houser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.